CD47 and cancer: Furthermore, hybrid CMNs repolarize tumor‐associated macrophages into the M1 phenotype, blocking the CD47–SIRPα signaling pathway, enhancing macrophage‐mediated phagocytosis of cancer cells, improving T cell immunity against cancer, and reducing systemic‐infusion‐induced side effects.[84]